Cargando…
Immunotherapy for Multiple Myeloma
Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a largely incurable disease with poor prognosis in high-risk patients, and thus new treatment strategies are needed to achieve treatment breakthroughs. MM represents various forms of impaired immune surveillance charac...
Autores principales: | Tamura, Hideto, Ishibashi, Mariko, Sunakawa, Mika, Inokuchi, Koiti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966649/ https://www.ncbi.nlm.nih.gov/pubmed/31842518 http://dx.doi.org/10.3390/cancers11122009 |
Ejemplares similares
-
PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020) -
Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018) -
Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2021) -
A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma treatment
por: Moriya, Keiichi, et al.
Publicado: (2016) -
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
por: Asayama, Toshio, et al.
Publicado: (2017)